Phase III randomized trial of PSMA PET prior to definitive radiation therapy for unfavorable intermediate-risk or high-risk prostate cancer [PSMA dRT]: Study protocol NCT04457245.

被引：1

作者：

Calais, Jeremie ^{[1
]}

Zhu, Shaojun ^{[2
]}

Hirmas, Nader ^{[3
]}

Eiber, Matthias ^{[4
]}

Hadaschik, Boris A. ^{[5
]}

Stuschke, Martin ^{[6
,7
]}

Herrmann, Ken ^{[8
]}

Czernin, Johannes ^{[1
]}

Kishan, Amar Upadhyaya ^{[9
]}

Nickols, Nicholas George ^{[10
]}

Elashoff, David ^{[1
]}

Fendler, Wolfgang Peter ^{[3
]}

机构：

[1] Univ Calif Los Angeles, Los Angeles, CA USA

[2] Univ Calif Los Angeles, Dept Mol & Med Pharmacol, Ahmanson Translat Theranost Div, Los Angeles, CA USA

[3] Univ Essen Gesamthsch, Essen, Germany

[4] Tech Univ Munich, Munich, Germany

[5] Vancouver Prostate Ctr, Vancouver, BC, Canada

[6] German Canc Consortium DKTK Core Ctr Heidelberg, Essen, Germany

[7] DKTK Partner Site Essen, Essen, Germany

[8] Univ Hosp Essen, Essen, Germany

[9] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA

[10] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA

来源：

关键词：

D O I：

10.1200/JCO.2021.39.6_suppl.TPS172

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

TPS172

引用

页数：3